Payment overview · 2025
General Payments
$1,085.50
53 reported records · 13 companies
Healthcare provider profile · identity verified
Gregory Scott Cheatham, MD
Allopathic & Osteopathic Physicians|Family Medicine · DECATUR, AL · NPI 1003844754
Verified facts
What the public records show
CMS Open Payments records show Gregory Scott Cheatham, MD received $1,085.50 in general payments during 2025 across 53 reported records.
ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) accounted for 23.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 22 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Kerendia, Mounjaro, Ozempic, Rexulti, Rybelsus, Xyosted.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Synthroid by this doctor in 2024.
Antares Pharma, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XYOSTED as an associated drug or biological on 18015 records involving 7619 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Xyosted by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 117 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Symbicort by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Kerendia by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 228 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 161 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 143 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Rybelsus by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Rexulti by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 220 claims for Eliquis by this doctor in 2024.
SANOFI-AVENTIS U.S. LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LANTUS as an associated drug or biological on 12 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Lantus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $259.62 | 23.9% | 13 | 2025 |
| Indivior Inc. | Unresolved — no canonical attribution shown | $160.39 | 14.8% | 5 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $158.20 | 14.6% | 8 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $85.54 | 7.9% | 4 | 2025 |
| Antares Pharma, Inc. | Unresolved — no canonical attribution shown | $82.20 | 7.6% | 3 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $59.78 | 5.5% | 4 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $57.81 | 5.3% | 3 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $51.29 | 4.7% | 3 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $47.84 | 4.4% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $46.84 | 4.3% | 3 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $38.73 | 3.6% | 2 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $21.55 | 2.0% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $15.71 | 1.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,085.50 | 53 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $259.62 | 13 | 2025 |
Source payment records
|
|||||
| SUBLOCADE Normalized: sublocade |
Drug | Indivior Inc. | $160.39 | 5 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $89.29 | 4 | 2025 |
Source payment records
|
|||||
| XYOSTED Normalized: xyosted |
Drug | Antares Pharma, Inc. | $82.20 | 3 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $70.24 | 3 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $70.24 | 3 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $59.78 | 4 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $54.14 | 2 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $51.29 | 3 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $50.37 | 3 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $47.84 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $43.96 | 3 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $38.73 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $33.53 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $33.53 | 2 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $24.28 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $21.55 | 2 | 2025 |
Source payment records
|
|||||
| VYNDAMAX Normalized: vyndamax |
Drug | PFIZER INC. | $17.69 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $15.71 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $15.30 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $14.55 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $14.55 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 117 | exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 23 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 161 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 143 | exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 31 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 18 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| XYOSTED xyosted |
2025 | Xyosted | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
40 | 15 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
33 | suppressed by CMS |
| Antares Pharma, Inc. Exact reporting entity; no affiliate inference |
2025 | XYOSTED open payments reported associated product |
CMS Open Payments — General Payments 18015 supporting records · 7619 recipient NPIs · example record 1235880452 |
Xyosted · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
117 | 32 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
228 | 52 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
161 | 35 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
143 | 37 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
220 | 71 |
| SANOFI-AVENTIS U.S. LLC Exact reporting entity; no affiliate inference |
2025 | LANTUS open payments reported associated product |
CMS Open Payments — General Payments 12 supporting records · 11 recipient NPIs · example record 1233196856 |
Lantus · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 903 | 160 |
| Atorvastatin Calcium | Atorvastatin Calcium | 848 | 266 |
| Gabapentin | Gabapentin | 710 | 157 |
| Omeprazole | Omeprazole | 681 | 211 |
| Levothyroxine Sodium | Levothyroxine Sodium | 669 | 222 |
| Amlodipine Besylate | Amlodipine Besylate | 577 | 187 |
| Losartan Potassium | Losartan Potassium | 545 | 186 |
| Furosemide | Furosemide | 482 | 177 |
| Lisinopril | Lisinopril | 447 | 133 |
| Metformin Hcl | Metformin Hcl | 375 | 124 |
| Montelukast Sodium | Montelukast Sodium | 336 | 88 |
| Potassium Chloride | Potassium Chloride | 296 | 101 |
| Alprazolam | Alprazolam | 290 | 52 |
| Hydrochlorothiazide | Hydrochlorothiazide | 289 | 88 |
| Pantoprazole Sodium | Pantoprazole Sodium | 289 | 105 |
| Simvastatin | Simvastatin | 276 | 82 |
| Metoprolol Succinate | Metoprolol Succinate | 274 | 86 |
| Trazodone Hcl | Trazodone Hcl | 258 | 83 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 245 | 97 |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 234 | 33 |
| Jardiance | Empagliflozin | 228 | 52 |
| Carvedilol | Carvedilol | 226 | 81 |
| Tamsulosin Hcl | Tamsulosin Hcl | 221 | 70 |
| Eliquis | Apixaban | 220 | 71 |
| Clopidogrel | Clopidogrel Bisulfate | 213 | 65 |
| Quetiapine Fumarate | Quetiapine Fumarate | 212 | 65 |
| Tramadol Hcl | Tramadol Hcl | 208 | 46 |
| Clonazepam | Clonazepam | 206 | 34 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 201 | 64 |
| Citalopram Hbr | Citalopram Hydrobromide | 189 | 48 |
| Sertraline Hcl | Sertraline Hcl | 180 | 58 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 177 | 46 |
| Hydralazine Hcl | Hydralazine Hcl | 174 | 53 |
| Methocarbamol | Methocarbamol | 174 | 56 |
| Meloxicam | Meloxicam | 167 | 64 |
| Duloxetine Hcl | Duloxetine Hcl | 165 | 52 |
| Fluticasone Propionate | Fluticasone Propionate | 165 | 59 |
| Metoprolol Tartrate | Metoprolol Tartrate | 164 | 45 |
| Mounjaro | Tirzepatide | 161 | 35 |
| Donepezil Hcl | Donepezil Hcl | 155 | 40 |
| Pregabalin | Pregabalin | 155 | 41 |
| Escitalopram Oxalate | Escitalopram Oxalate | 151 | 47 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 145 | 38 |
| Methylprednisolone | Methylprednisolone | 143 | 121 |
| Ozempic | Semaglutide | 143 | 37 |
| Pravastatin Sodium | Pravastatin Sodium | 143 | 43 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 141 | 44 |
| Azithromycin | Azithromycin | 139 | 124 |
| Januvia | Sitagliptin Phosphate | 128 | 26 |
| Famotidine | Famotidine | 127 | 54 |
| Tizanidine Hcl | Tizanidine Hcl | 127 | 43 |
| Benazepril Hcl | Benazepril Hcl | 121 | 34 |
| Farxiga | Dapagliflozin Propanediol | 117 | 32 |
| Fluconazole | Fluconazole | 117 | 61 |
| Cefdinir | Cefdinir | 114 | 104 |
| Pioglitazone Hcl | Pioglitazone Hcl | 113 | 36 |
| Prednisone | Prednisone | 112 | 47 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 110 | 14 |
| Lorazepam | Lorazepam | 107 | 34 |
| Sucralfate | Sucralfate | 104 | 37 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 104 | 24 |
| Ropinirole Hcl | Ropinirole Hcl | 103 | 24 |
| Zolpidem Tartrate | Zolpidem Tartrate | 103 | 19 |
| Ondansetron Odt | Ondansetron | 99 | 41 |
| Buspirone Hcl | Buspirone Hcl | 97 | 25 |
| Memantine Hcl | Memantine Hcl | 97 | 20 |
| Ondansetron Hcl | Ondansetron Hcl | 95 | 34 |
| Xarelto | Rivaroxaban | 95 | 34 |
| Spironolactone | Spironolactone | 94 | 37 |
| Allopurinol | Allopurinol | 91 | 34 |
| Celecoxib | Celecoxib | 89 | 27 |
| Levofloxacin | Levofloxacin | 84 | 61 |
| Paroxetine Hcl | Paroxetine Hcl | 84 | 17 |
| Alendronate Sodium | Alendronate Sodium | 76 | 22 |
| Glimepiride | Glimepiride | 75 | 27 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 73 | 60 |
| Aripiprazole | Aripiprazole | 71 | 18 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 70 | 27 |
| Metformin Hcl Er | Metformin Hcl | 69 | 21 |
| Promethazine Hcl | Promethazine Hcl | 69 | 19 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 68 | 25 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 67 | 61 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 66 | 22 |
| Fluoxetine Hcl | Fluoxetine Hcl | 65 | 22 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 65 | 26 |
| Entresto | Sacubitril/Valsartan | 60 | 14 |
| Oxycodone Hcl | Oxycodone Hcl | 59 | 12 |
| Fenofibrate | Fenofibrate | 58 | 16 |
| Nystatin | Nystatin | 57 | 31 |
| Amitriptyline Hcl | Amitriptyline Hcl | 55 | 20 |
| Valacyclovir | Valacyclovir Hcl | 55 | 21 |
| Atenolol | Atenolol | 54 | 18 |
| Glipizide | Glipizide | 53 | 16 |
| Testosterone Cypionate | Testosterone Cypionate | 52 | 13 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 51 | 19 |
| Doxycycline Hyclate | Doxycycline Hyclate | 49 | 43 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 49 | 18 |
| Diclofenac Sodium | Diclofenac Sodium | 47 | 22 |
| Levetiracetam | Levetiracetam | 44 | 14 |
| Estradiol | Estradiol | 43 | 14 |
| Mirtazapine | Mirtazapine | 42 | 11 |
| Clonidine Hcl | Clonidine Hcl | 41 | 17 |
| Finasteride | Finasteride | 41 | 13 |
| Linzess | Linaclotide | 40 | 15 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 40 | 16 |
| Bupropion Hcl Sr | Bupropion Hcl | 39 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 39 | 23 |
| Digoxin | Digoxin | 38 | 16 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 37 | suppressed |
| Glipizide Er | Glipizide | 36 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 35 | suppressed |
| Cephalexin | Cephalexin | 33 | 29 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 33 | suppressed |
| Mupirocin | Mupirocin | 33 | 28 |
| Naproxen | Naproxen | 33 | 20 |
| Synthroid | Levothyroxine Sodium | 33 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 33 | suppressed |
| Ibuprofen | Ibuprofen | 32 | 14 |
| Meclizine Hcl | Meclizine Hcl | 32 | 18 |
| Propranolol Hcl | Propranolol Hcl | 32 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 31 | 15 |
| Breo Ellipta | Fluticasone/Vilanterol | 31 | 11 |
| Colchicine | Colchicine | 31 | 13 |
| Repatha Sureclick | Evolocumab | 31 | suppressed |
| Rexulti | Brexpiprazole | 31 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 30 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 30 | suppressed |
| Verapamil Er | Verapamil Hcl | 30 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 29 | suppressed |
| Myrbetriq | Mirabegron | 28 | 11 |
| Dicyclomine Hcl | Dicyclomine Hcl | 27 | suppressed |
| Hydrocortisone | Hydrocortisone | 27 | suppressed |
| Ranolazine Er | Ranolazine | 27 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 27 | 22 |
| Sumatriptan Succinate | Sumatriptan Succinate | 27 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 27 | 13 |
| Valsartan | Valsartan | 27 | 11 |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 26 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 26 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 26 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 26 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 26 | 12 |
| Nifedipine Er | Nifedipine | 26 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 26 | suppressed |
| Metronidazole | Metronidazole | 25 | 21 |
| Trulicity | Dulaglutide | 25 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 24 | suppressed |
| Sotalol | Sotalol Hcl | 24 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 24 | suppressed |
| Torsemide | Torsemide | 24 | suppressed |
| Trulance | Plecanatide | 24 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 23 | suppressed |
| Diazepam | Diazepam | 23 | suppressed |
| Febuxostat | Febuxostat | 23 | suppressed |
| Kerendia | Finerenone | 23 | suppressed |
| Lansoprazole | Lansoprazole | 23 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 22 | suppressed |
| Baclofen | Baclofen | 21 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 21 | suppressed |
| Primidone | Primidone | 21 | suppressed |
| Buprenorphine Hcl | Buprenorphine Hcl | 20 | suppressed |
| Gemfibrozil | Gemfibrozil | 20 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 20 | suppressed |
| Temazepam | Temazepam | 20 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 20 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 19 | 16 |
| Ezetimibe | Ezetimibe | 19 | suppressed |
| Gemtesa | Vibegron | 19 | suppressed |
| Indapamide | Indapamide | 19 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 19 | 18 |
| Terazosin Hcl | Terazosin Hcl | 19 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 18 | suppressed |
| Fosinopril Sodium | Fosinopril Sodium | 18 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 18 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 18 | suppressed |
| Premarin | Estrogens, Conjugated | 18 | suppressed |
| Rybelsus | Semaglutide | 18 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 17 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 17 | 11 |
| Lovastatin | Lovastatin | 17 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 16 | suppressed |
| Lidocaine | Lidocaine | 16 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 16 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 15 | suppressed |
| Dutasteride | Dutasteride | 15 | suppressed |
| Fesoterodine Fumarate Er | Fesoterodine Fumarate | 15 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 15 | suppressed |
| Levemir Flexpen | Insulin Detemir | 15 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 15 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 15 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 15 | suppressed |
| Olanzapine | Olanzapine | 15 | suppressed |
| Risperidone | Risperidone | 15 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 14 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 14 | suppressed |
| Klor-Con M10 | Potassium Chloride | 14 | suppressed |
| Tramadol Hcl Er | Tramadol Hcl | 14 | suppressed |
| Betamethasone Valerate | Betamethasone Valerate | 13 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 13 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 13 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 13 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 12 | suppressed |
| Chlorthalidone | Chlorthalidone | 12 | suppressed |
| Fenofibric Acid | Fenofibric Acid (Choline) | 12 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 12 | suppressed |
| Latanoprost | Latanoprost | 12 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 12 | suppressed |
| Testosterone | Testosterone | 12 | suppressed |
| Zonisamide | Zonisamide | 12 | suppressed |
| Atropine Sulfate | Atropine Sulfate | 11 | suppressed |
| Brilinta | Ticagrelor | 11 | suppressed |
| Concerta | Methylphenidate Hcl | 11 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 11 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 11 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 11 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 11 | suppressed |
| Nitroglycerin | Nitroglycerin | 11 | suppressed |
| Norethindrone | Norethindrone | 11 | suppressed |
| Topiramate | Topiramate | 11 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 11 | suppressed |
| Xyosted | Testosterone Enanthate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,085.50 · 53 records | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | AIRSUPRA, BREZTRI, CAPLYTA, FARXIGA, Kerendia, MOUNJARO, NURTEC ODT, OTEZLA, Ozempic, QULIPTA, REPATHA, REXULTI, Rybelsus, SUBLOCADE, TZIELD, UBRELVY, VOQUEZNA, VRAYLAR, VYNDAMAX, Wegovy, XYOSTED, ZAVZPRET | 15 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error